Validation of the DBP-6279B arm-type fully automatic digital blood pressure monitor in pregnancy according to the ISO 81060-2:2018/AMD 1:2020 protocol

To determine whether there is significant disparity in blood pressure between the two arms. Prospective, observational study. One general hospital in Birmingham, England. Four hundred participants [age 56.3 +/- 19.7 years (mean +/- SD), 50% male] were recruited from staff and patients. Simultaneous bilateral blood pressure measurements were obtained using Omron HEM-705CP automated oscillatory devices; with two measurements taken in each arm. Mean inter-arm blood pressure differences and frequency of clinically important disparities. Mean +/- SD inter-arm differences in systolic and diastolic blood pressure were 1.81 +/- 8.6 mmHg and -0.23 +/- 8.3 mmHg, respectively. The analogous figures for mean +/- SD absolute differences were 6.32 +/- 6.12 mmHg and 5.06 +/- 6.57 mmHg, respectively. Significant differences were present between the mean right and left arm systolic blood pressure [t(399) = 4.20, P < 0.0001], and the mean absolute difference for both systolic [t(399) = 20.65; P < 0.0001] and diastolic [t(399) = 15.39; P < 0.0001] blood pressure. The variation in mean inter-arm blood pressure was unrelated to age, sex, ethnicity, arm circumference, handedness, being hypertensive, diabetic, or previous history of cardiovascular disease. Clinically significant inter-arm differences in systolic blood pressure of > 10 and > 20 mmHg were found in 20 and 3.5%, respectively; diastolic differences of > 10 and > 20 mmHg were present in 11 and 3.5%, respectively. Age was the only significant predictor of clinically significant variations in inter-arm blood pressures and mean absolute blood pressure differences. Significant differences in mean inter-arm systolic blood pressure, and mean absolute inter-arm systolic and diastolic blood pressure are present. This emphasizes the importance of measuring blood pressure in both arms initially to prevent this misdiagnosis of hypertension, due to normal differences in blood pressure between the arms.

Objective: The blood pressure (BP) lowering effect of renal sympathetic denervation (RDN) in treatment resistant hypertension (TRH) shows variation among the few randomized studies. The duration of antihypertensive effect and long-term effect and safety of RDN requires further follow-up. We aimed to report the office, ambulatory blood pressure changes as well as long-term safety at 3 years follow-up in our Oslo-RDN study.Design and method: Patients with apparent TRH (n = 65) were referred specifically for RDN and those with secondary and spurious hypertension (n = 26) were excluded. TRH was defined as office systolic BP > 140 mmHg despite maximally tolerated doses of at least 3 antihypertensive drugs including a diuretic. Furthermore, ambulatory daytime systolic BP > 135 mmHg following witnessed intake of antihypertensive drugs was required. This procedure revealed that 20 patients had normalized BP, indicating poor adherence, and these patients were excluded. Patients with true TRH were randomized and underwent RDN with Symplicity catheter (n = 9) versus adjusted drug treatment (n = 10). Patients came for follow-up 3–4 years after baseline. Results: 24-hour ambulatory systolic and diastolic BPs in the drug adjustment group changed from 151 ± 13/84 ± 7 mmHg at baseline to 132 ± 15/77 ± 6 mmHg at 3-years, and in the RDN group from 149 ± 9/89 ± 7 mmHg at baseline to 137 ± 13/81 ± 10 mmHg at 3-years follow-up. Office, daytime and nighttime ambulatory BPs changed in parallel to the 24-hour ambulatory BPs. The absolute differences in systolic or diastolic BPs between the groups were consistent with earlier follow up points with a tendency toward a smaller difference between the groups. The difference in systolic BP at long-term follow up was not significant (p = 0.34). There were no significant changes in renal arteries assessed by MRI or CT scans at long-term follow-up. No deterioration of renal function was observed. Conclusions: The results at the three-year follow-up are consistent with earlier time points, with a tendency toward a smaller difference in BPs between the TRH and RDN groups. Our data support that RDN is a safe procedure on long-term follow-up and this allows further research to identify characteristics of patients who might respond to RDN.

BACKGROUND: Syndrome nephrotic is the most common kidney disease found in pediatric kidney disease, classification based on clinical response to steroids or histopathological characteristics. Increased blood pressure in steroid-resistant nephrotic syndrome (NS) is still a complication to be aware of in cases of NS. AIM: The aim of the study was to determine the differences in systolic and diastolic blood pressure in patients with steroid-sensitive NS and steroid-resistant NS. METHODS: Analytical correctional study in 50 children with NS divided into 25 Steroid Resistant NS (SRNS) groups and 25 steroid sensitive NS (SSNS) people who met inclusion and exclusion criteria to assess systolic and diastolic blood pressure in each group in pediatric nephrology division of the general hospital of Haji Adam Malik Medan. RESULTS: There is a difference in systolic blood pressure in the SRNS and SSNS groups which mean p = 0.024 and there is no difference in diastolic blood pressure in the SRNS group with SSNS p = 0.358. If linked levels of proteinuria to blood pressure, systolic and diastolic in both groups found no significant link p&gt;0.05 high blood pressure with the degree of proteinuria in both group. CONCLUSION: There are differences in systolic blood pressure in the SRNS and SSNS groups.

Lifestyle modification continues to be an important initial strategy in both the prevention and treatment of hypertension as recommended in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Clinical trials have documented that weight loss, sodium restriction, alcohol restriction, and increasing physical activity may help prevent, as well as treat, hypertension. While the effects of dietary macronutrients on blood pressure (BP) have not been as well studied, the most effective dietary approach to lowering BP involves a diet rich in fruits, vegetables, and lowfat dairy products, i.e., the Dietary Approaches to Stop Hypertension (DASH) diet. The DASH diet involves a modest increase in dietary animal and vegetable protein. Other clinical trials studying dietary protein intake and reduction in BP have produced conflicting results. He and colleagues conducted a randomized, double-blind, multicenter, controlled trial of a diet rich in soybean protein compared to a complex carbohydrate control diet in 302 adult Chinese subjects with stage 1 hypertension (systolic BP ≥140 mm Hg, diastolic BP ≥90 mm Hg, or both) or prehypertension (systolic BP 120 mm Hg-139 mm Hg; diastolic BP 80 mm Hg-89 mm Hg) from three communities in the People's Republic of China. Demographic and dietary characteristics were similar in the three communities and were made up of men and women 35–64 years of age. Trial participants had not been on any antihypertensive medication for at least 2 months and had no underlying cardiovascular or renal disease or diabetes. Of interest, they had restricted their alcohol use to no more than 21 drinks per week. Subjects were randomized to 12 weeks of supplementation with 40 g/d of isolated soybean protein or 40 g of complex carbohydrate from wheat, both given in the form of cookies. The daily nutritional content of the cookies was similar except for their dietary protein content (49 g vs. 12.9 g) and carbohydrate content (64.8 g vs. 95.3 g), soybean and control groups, respectively. The daily portion of the soybean protein cookies contained 76.4 mg of total isoflavone. On entry, average systolic BP was between 130-159 mm Hg (mean 135 mm Hg) and average diastolic BP was between 80-99 mm Hg (mean 84.7 mm Hg) based on an average of nine readings (three observations at each of three screening visits). BP readings were obtained at follow-up visits 6 and 12 weeks after randomization. Trained research staff conducted a 24-hour dietary recall at the screening visit, the 6-week visit, and the 12-week visit. A 24-hour urine specimen was obtained at the same time periods to measure urinary sodium and potassium. Side effects (15 items) were evaluated using a standard questionnaire at the 12-week follow-up visit. The primary outcome was the net difference in change (final follow-up - baseline) of systolic and diastolic BP between the study groups. After 12 weeks, approximately 90% of both study groups completed the study and 92% of both groups adhered to their dietary intervention. Urinary excretion of sodium decreased and urinary excretion of potassium increased to a similar extent in both groups with no significant differences in body weight. There was a significant reduction in both systolic (−4.3 mm Hg) and diastolic (−2.76 mm Hg) BP in subjects on the soy protein supplement. Differences between the treatment groups were greater among subjects with hypertension (−7.88 mm Hg systolic and −5.27 mm Hg diastolic) than among people with prehypertension (−2.34 mm Hg systolic and −1.28 mm Hg diastolic). Favorable effects on BP reduction occurred in both men and women, in younger and older subjects, as well as in obese and nonobese individuals. Rates of adverse effects did not differ between the groups. In this short-term, 12-week study, increased intake of vegetable protein, in the form of soybean supplementation, resulted in reductions in both systolic and diastolic BP. Whether this favorable effect on BP is due to the vegetable protein or isoflavone content in soybeans remains unclear.—He J, Gu D, Wu X, et al. Effect of soybean protein on blood pressure: a randomized, controlled trial. Ann Intern Med. 2005;143:l-9. While observational studies have suggested that soybean protein supplementation lowers BP, several small clinical trials have previously reported inconsistent findings. Most clinical trials that have evaluated the effects of an increased intake of dietary protein on BP have had a small sample size, did not systematically evaluate BP, and did not use changes in BP as the primary outcome of interest. The present study, with the largest sample size and several well-executed measurements of BP, suggests that soybean supplementation reduces both systolic and diastolic BP. This effect was consistent regardless of gender, age, and body weight. The effect noted was greatest in people with hypertension, with less of an effect in prehypertensive individuals. While not powered to evaluate subgroups, this study suggests that soybean protein supplementation is more important for treating hypertension than for preventing it. This was not a forced feeding study like the DASH trial. By using 24-hour dietary recall, the authors found that subjects increased their dietary protein intake by only 26 g, less than the targeted 40 g. It also remains unclear whether the favorable effect on BP reduction is due to soybean protein or isoflavone content: this needs to be evaluated in future trials. In addition, since there has been an association between soy protein and bladder cancer in two cohort studies, this association needs further clarification before we can promote this recommendation. Further research is necessary to determine the mechanistic benefits of soybean protein supplementation on BP reduction. Proposed mechanisms include the vasodilatory protein components of soybean; the soybean associated dietary increase in arginine, the metabolic precursor of NO; or an improvement in insulin sensitivity. Although recommended as first-line therapy in the treatment of hypertension, physicians have remained pessimistic over the ability of lifestyle modification, including nutritional intervention, to effectively prevent as well as treat hypertension. The current findings suggest that increasing consumption of soybean protein may be useful in treating hypertension. As dietary protein in China is mainly derived from plant foods (not from animal foods as in the United States) and with the average dietary protein intake of 69 g/d in this Chinese study (whereas the average dietary protein intake in the United States is 79 g/d [National Health and Nutrition Examination Survey (NHANES III)]), the authors appropriately wonder whether their study findings can directly apply to the US population. Before we recommend increased soybean protein intake as a means of treating and preventing hypertension, further evidence of safety, feasibility, and efficacy in this country is required. At present, we should continue to recommend the DASH diet, providing an increased amount of both animal and vegetable protein in our diet. Ginseng is a commonly used herbal supplement that grows in the temperate regions of Asia and North America. Currently, about 4.5% of Americans use it. Like many supplements, the safety and efficacy of ginseng is not well studied in individuals with hypertension. Ginseng's exact mechanism of action is unknown. Previous reports have suggested that ginseng may increase blood pressure (BP), while other reports have shown a neutral effect. The ginseng currently used is often a blend of several species of ginseng, which vary in their ginsenoside content, the component believed to be responsible for its effect on blood pressure. The two most consumed species in the United States are Panax ginseng and Panax quinquefolius, also known as North American ginseng (NAG). In the current clinical trial, Canadian investigators examined the acute effects of NAG on BP in individuals with hypertension. Nineteen individuals, aged 18-75 years, with hypertension (defined as systolic BP >140 mm Hg or diastolic BP >90 mm Hg) at each of three separate prestudy visits or on antihypertensive medications provided informed consent. Exclusion criteria included secondary hypertension, diabetes mellitus, kidney or liver disease, unstable angina, change in body weight of >2.2 kg between visits, or use of any herbal supplements in the previous 2 months or during the study. Sixteen participants (12 men and 4 women, mean age of 61 years, with a mean BP 132/83 mm Hg) completed the study. Thirteen of the 16 individuals were on antihypertensive therapy on entry. Each participant, serving as their own control, was randomized in a double-blind fashion to six different batches of 3-mg NAG and two identical 3-mg corn starch placebo tablets. The batches of NAG were selected by the Ontario Ginseng Growers Association to represent the spectrum of NAG available on the market; they were carefully examined for quality. Each NAG root batch (or placebo) was ground into a powder and packed into identical capsules by a technician blinded to study allocation. On eight consecutive mornings, participants arrived at the study center in a fasting state, did not take their prescribed antihypertensive medications, and were fitted with an ambulatory BP monitor. Office and ambulatory BP readings (5-minute intervals for 30 minutes using SpaceLabs 90207, SpaceLabs Medical, Inc., Issaquah, Washington) were taken at baseline and 60 minutes after administration of study medication (corresponding to peak plasma concentrations of NAG). For each batch of NAG and placebo, the post-treatment change in systolic BP, diastolic BP, and pulse pressure per individual relative to baseline were calculated at 10-minute intervals and averaged. In addition, each batch of NAG had its ginsenoside content determined by high-performance liquid chromatography. All six NAG samples showed a comparable content of ginsenosides. No significant differences in mean systolic BP, diastolic BP, or pulse pressure at each of the 10-minute intervals or over the entire 160-minute post-treatment period were seen between the six individual NAG and placebo treatments. Taken together, and compared with placebo, the NAG treatments increased systolic and diastolic BP slightly at 140 and 160 minutes, respectively, but decreased diastolic BP slightly at 100 minutes. Overall, there was no significant difference between the average of the NAG batches and placebo on total post-treatment change in systolic BP, diastolic BP, and pulse pressure. The authors conclude that NAG exerts a neutral acute effect on BP in hypertensive individuals.—Stavro PM, Woo M, Heim TF, et al. North American ginseng exerts a neutral effect on blood pressure in individuals with hypertension. Hypertension. 2005;46:406-411. Roughly one third of adults use neutraceuticals, and 15 million Americans use them together with conventional medicines. Their use is of tremendous importance to the hypertension community. A recent prevalence study from the Mayo Clinic found that 61% of people 18 years of age and older had used a neutraceutical over the past year. These “dietary supplements,” defined as a vitamin, mineral, herb, or other botanical, are excluded from the rigorous scientific evaluation that ensures both the safety and the effectiveness required of “drugs” presented before the FDA. These products are often promoted and accepted by the public to positively affect one's health, despite their lack of certainty for benefit. With sales of neutraceutical products increasing 25% per year in the United States, their influence on BP control continues to be of great importance. Nine million American adults use ginseng, and it continues to be popular among patients with hypertension. In many cases, its safety and efficacy is undocumented. One concern has been a lack of standardization of available preparations. In this evaluation, Canadian investigators working with the Ontario Ginseng Growers Association took great trouble to ensure that they were using a sample that represented the spectrum of what is currently available on the market. Even so, the study is limited to only one type of commonly used ginseng root, NAG. The other ginseng root commonly used, Panax ginseng, was not used in this trial, but a previous investigation by the same investigators demonstrated that in steamed form, Panax ginseng caused a modest decline in BP with acute administration. The authors postulate that perhaps the disparate effects on BP between the two species may be due to the presence of ginosenoside Rg3, which is found in Panax ginseng but not in NAG. As opposed to regulated prescription medications, the safety and efficacy of one formulation of an herbal supplement should not necessarily be extrapolated to other formulations that may vary considerably in active ingredient content. While this well-designed, clinical trial using ambulatory BP monitoring describes the acute effects of ginseng on BP, it is limited by its small sample size, low dosage used, lack of concomitant antihypertensive medication administration, and sole focus on the acute BP changes associated with a single dose of ginseng. While the available evidence suggests that patients with hypertension need not avoid either NAG or Panax ginseng due to concerns about acute BP elevation, further investigations will determine its safety and efficacy with chronic administration in hypertensive patients. At present, ginseng should not be recommended for individuals with hypertension.

Hypertension that is not controlled and occurs in the long term will affect all body organ systems resulting in various complications that can cause death. To prevent complications in hypertension, it is necessary to control hypertension, one of which is by complementary therapy in the form of acupressure and cupping. This study aims to determine differences in blood pressure in patients with hypertension after acupressure therapy combined with cupping therapy with wet cupping therapy. The type of research is Quasy Experiment with pre-post test with a control group design. The study was conducted at the Asy-Syaafi Holistic Center with a sample of 34 hypertension patients where 14 respondents were in the intervention group and 14 respondents in the control group. The data analyst used the Independent T-test. The results found that there was no difference in systolic blood pressure (p-value 0.800) and diastolic (p-value 0.274) between the intervention group and the control group, but there was a significant difference in systolic blood pressure (p-value 0.000) and diastolic (p-value 0.002) in the intervention group. before and after cupping acupressure therapy and there was a difference in systolic (p value 0.000) and diastolic (p value 0.000) blood pressure in the control group before and after wet cupping therapy. it can be concluded that there is no difference in blood pressure between the group given acupressure combination cupping therapy and the group given wet cupping therapy alone.

The aim of this study was to determine the influence of change of posture on blood pressure as recorded with an automatic ambulatory blood pressure monitor and a standard auscultatory device. The blood pressure difference between sitting and supine and between standing and supine posture was 1.1/3.9 and 6.5/6.3 mmHg, respectively, for the monitor recordings, and 0.7/6.7 and 7.9/14.8 mmHg, respectively, for the standard recordings. All differences were significant, except the systolic blood pressure difference between sitting and supine posture. There were no significant differences in systolic blood pressure between monitor and standard recordings in any posture. The corresponding differences in diastolic blood pressure were significant in sitting (-4.6 mmHg) and standing postures (-10.3 mmHg), but not in supine posture (-1.8 mmHg). It is concluded that a change of posture contributes to blood pressure variability, and agreement between diastolic blood pressure in supine subjects, as recorded by an ambulatory monitor and a standard device, does not necessarily mean agreement in standing (or sitting) subjects.

&#x0D; Hypertension often results in dangerous conditions that are often not realized and often do not cause complaints. Hypertension is also often referred to as the silent kiler because it is a deadly disease. Even hypertension can lead to other deadly diseases and can increase the risk of heart attack, stroke and kidney failure.&#x0D; The research design used Quasi Experiment with Non Equivalent Control Group design with pre-postest control one group design. The research was conducted in the working area of ​​the Dlanggu Health Center on September 2020. The population in this study were all hypertension sufferers. The sampling technique used simple random sampling of 60 people. The instrument used was a sphygmomanometer, measuring height and weight and an observation sheet. Data analysis used the Ancova test with the assumption of normal and homogeneous data distribution.&#x0D; Ancova analysis results showed that BMI did not affect systolic blood pressure (F = 0.014, p value 0.907&gt; α), but there was a difference in systolic blood pressure between the control group and the treatment group (F = 105.06, p-value 0,000 &lt;α). The results of the ancova analysis showed that BMI did not affect diastolic blood pressure (F = 0.003, p value 0.953&gt; α), but there was a difference in diastolic blood pressure between the control group and the treatment group (F = 80.899, p-value 0.000 &lt;α). It can be concluded that the difference in systolic and diastolic blood pressure after being given Touch Therapy is not controlled by the BMI variable. This is because blood pressure is controlled by other influencing factors, including stress and physical activity.&#x0D;

Inter-arm difference in blood pressure is the difference in the systolic and the diastolic blood pressure between arms of an individual. According to American heart association, interarm Blood Pressure difference of more than 10 mm of Hg are associated with peripheral vascular disease. The present study aims to determine the magnitude of interarm difference in young healthy individuals and to assess whether family history of hypertension, age, sex and Body mass index is related to higher interarm difference Methods: A cross-sectional study was carried out among 270 students of Manipal College of Medical Sciences, Pokhara, Nepal. Blood pressure was measured in both the arms using a mercury sphygmomanometer. (Elko 300) Statistical analysis was done using paired t test, chi-square and Pearson's correlation test using SPSS 23. The absolute mean Inter-arm difference for systolic blood pressure was 11.03±0.67mm Hg and for diastolic blood pressure was 6.020 ±0.21 mm Hg. There is significant inter-arm difference for systolic blood pressure and diastolic blood pressure (p<0.001). Inter-arm systolic blood pressure difference was significantly associated with family history of hypertension, age and Body Mass Index (p<0.001) Meanwhile, there was no statistically significant association of sex, family history of hypertension, age and Body Mass Index with inter-arm difference for diastolic blood pressure. Significant inter-arm systolic and diastolic blood pressure differences was found in the young, healthy population. Positive correlation of increased Inter-arm difference in Blood Pressure with family history of hypertension was confirmed. This emphasizes the importance of measuring blood pressure in both arms to be a routine practice as we aim for early diagnosis and prompt treatment of hypertensive disorders.

In 1975-1978, the Chicago Department of Health conducted a screening program that included measurements of blood pressure, heart rate, height, weight, triceps skinfold thickness, and arm circumference, and calculation of body mass index and muscle circumference for non-public school children. Based on data on 4,086 boys and girls aged 5-10 years from the program, this study examined the ethnic differences in blood pressure and heart rate among children of white, black, Latino, and Oriental ethnicity. Mean levels for both systolic and diastolic blood pressure were higher for Oriental and black children than for white and Latino children. These differences were independent of age, height, weight, and skinfold thickness. The black children had a much lower mean heart rate than the other children. A seasonal variation was observed for systolic blood pressure, i.e., with each sex group, the mean systolic blood pressure adjusted for age, skinfold thickness, and height tended to be higher in spring than in fall and winter. (Note-- no child was screened during the summer because of summer break.) With control for season, ethnic differences in systolic blood pressure disappeared, but not the ethnic differences in diastolic blood pressure and heart rate.

Aims: To investigate the role played by employees’ perceptions of their supervisors’ interactional styles as a possible source of workplace stress that may be associated with increased morbidity and mortality...

Ambulatory Blood Pressure in Chronic Kidney Disease: Ready for Prime Time?

Objective To explore if there is a difference in blood pressure in left and right extremities. Methods A total of 20 164 adults who took part in health check-up at Health Examination Center of Chinese PLA General Hospital between December 2009 and August 2011 were enrolled in this study.Age, height and body weight were recorded, and blood pressure in extremities was measured in synchronous way by using an arteriosclerosis detector. Results (1) Blood pressure in upper left extremity was slightly higher than that in upper and lower right extremity (all P=0.0001). (2) Difference in diastolic blood pressure in upper left and right limbs in females (2.1±6.7) mm Hg(1 mm Hg=0.133 kPa) was more significant than that in males (1.4±6.5) mm Hg (P=0.0000). In males, difference in systolic blood pressure between two lower extremities (2.3±9.6) mm Hg was more significant than that in females (1.9±13.4) mm Hg (P=0.0225). (3) The above mentioned differences were found in low or normal weight and over-weight/obesity populations, which was not correlated with body mess index.(4) The difference of diastolic blood pressure in left and right limbs of relatively taller adults (>170 cm) was more significant than that in shorter populations (<170 cm) (P=0.001). Conclusion The differences in blood pressure in left and right extremities do exist. Key words: Blood pressure; Extremities

Exercise when done regularly will give big impact to the body. One of the alteration in an athlete that can be made is the cardiovascular system change. This study aimed to discover the difference of heart rate and blood pressure between aerobic predominant athlete and anaerobic predominant athlete. The study design was case-control, data collected from 80 athletes divided into 40 aerobic predominant athletes (canoe, sail, gantole, shooting, and bicycle racing) and 40 anaerobic predominant athletes (weight lifting, taekwondo, softball, tarung derajat, and rock climbing) in KONI West Java, Bandung. Sample was collected by random sampling and analyzed by T test independent. The result showed there was significant difference of heart rate between aerobic predominant athlete and anaerobic predominant athlete (p=0,0001), and lower in aerobic. There was also no significant difference of systolic blood pressure between predominant aerobic athlete and predominant anaerobic athlete (p=0,404), and was higher in anaerobic. Another result showed no significant difference of diastolic blood pressure between predominant aerobic athlete and predominant anaerobic athlete (p=0,553) and was higher in anaerobic. In conclusion, there was significant difference of the heart rate, but no difference of systolic and diastolic blood pressure between aerobic predominant and anaerobic predominant athlete.

Exercise when done regularly will give big impact to the body. One of the alteration in an athlete that can be made is the cardiovascular system change. This study aimed to discover the difference of heart rate and blood pressure between aerobic predominant athlete and anaerobic predominant athlete. The study design was case-control, data collected from 80 athletes divided into 40 aerobic predominant athletes (canoe, sail, gantole, shooting, and bicycle racing) and 40 anaerobic predominant athletes (weight lifting, taekwondo, softball, tarung derajat, and rock climbing) in KONI West Java, Bandung. Sample was collected by random sampling and analyzed by T test independent. The result showed there was significant difference of heart rate between aerobic predominant athlete and anaerobic predominant athlete (p=0,0001), and lower in aerobic. There was also no significant difference of systolic blood pressure between predominant aerobic athlete and predominant anaerobic athlete (p=0,404), and was higher in anaerobic. Another result showed no significant difference of diastolic blood pressure between predominant aerobic athlete and predominant anaerobic athlete (p=0,553) and was higher in anaerobic. In conclusion, there was significant difference of the heart rate, but no difference of systolic and diastolic blood pressure between aerobic predominant and anaerobic predominant athlete.

Prognosis in Relation to Blood Pressure Variability